9.5% Below Target

The consensus price target for CNS is $82, close to the current price of $74.88 (9.5% implied move). Based on 13 analyst estimates, the stock appears fairly valued near current levels.

CNS has a consensus rating of "Sell" based on 13 Wall Street analysts. The rating breakdown is leaning bearish, with 5 Sell/Strong Sell ratings. The consensus 12-month price target of $82 implies 9.5% upside from current levels.

CNS trades at a forward P/E of 21.5793x, representing a moderate valuation. With analysts targeting $82 (9.5% implied move), the stock appears reasonably valued with upside.

The most bullish Wall Street analyst has a price target of $82 for CNS, while the most conservative target is $82. The consensus of $82 represents the median expectation. Our quantitative valuation model projects a bull case target of $108 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CNS is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CNS stock forecast based on 13 Wall Street analysts shows a consensus price target of $82, with estimates ranging from $82 (bear case) to $82 (bull case). The median consensus rating is "Sell". Our proprietary valuation model produces a base case fair value of $82, with bear/bull scenarios of $52/$108.

Our quantitative valuation model calculates CNS's fair value at $82 (base case), with a bear case of $52 and bull case of $108. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.

CNS trades at a forward P/E ratio of 21.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 25.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

CNS appears fairly valued according to analysts, with a "Sell" rating and minimal upside to the $82 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CNS analyst price targets range from $82 to $82, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $82 consensus represents the middle ground. Our model's $52-$108 range provides an independent fundamental perspective.